Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
AbbVie Files Migraine Med Atogepant in Japan
AbbVie said on March 14 that it has submitted a new drug application in Japan seeking regulatory approval for atogepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the preventive treatment of migraines in adults.The filing this time is…
To read the full story
Related Article
- Japan Panel OKs AbbVie’s Aquipta, Ipsen’s Sohonos, and Novo’s IcoSema for Approval
January 26, 2026
- Japan Panel to Review AbbVie’s Aquipta, Ipsen’s Sohonos on January 23
January 13, 2026
- AbbVie Files Atogepant for Acute Migraine Attacks in Japan
December 16, 2025
BUSINESS
- Santen CEO Paid 251 Million Yen in FY2025, COO Joins Disclosure List
June 19, 2026
- Teijin to Divest Feburic, Bonalon, Other Legacy Brands to LTL
June 18, 2026
- Acumen Exercises Option for Up to Two JCR-Enabled AD Candidates
June 18, 2026
- Takeda CEO Pulls in 2.3 Billion Yen in FY2025
June 18, 2026
- Elevidys Needs More Safety Data to Support Full Approval: Expert
June 18, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…